MIRM Mirum Pharmaceuticals, Inc.

Nasdaq mirumpharma.com


$ 69.97 $ 0.61 (0.88 %)    

Friday, 24-Oct-2025 15:59:59 EDT
QQQ $ 617.50 $ 6.52 (1.07 %)
DIA $ 472.45 $ 4.92 (1.05 %)
SPY $ 677.25 $ 5.49 (0.82 %)
TLT $ 91.47 $ 0.04 (0.04 %)
GLD $ 378.59 $ -1.27 (-0.34 %)
$ 70.02
$ 70.17
$ 68.95 x 50
$ 78.00 x 400
$ 69.34 - $ 70.64
$ 36.88 - $ 78.54
320,724
na
3.52B
$ 0.74
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-06-2025 06-30-2025 10-Q
2 05-07-2025 03-31-2025 10-Q
3 02-26-2025 01-01-1970 10-K
4 11-12-2024 09-30-2024 10-Q
5 08-07-2024 06-30-2024 10-Q
6 05-08-2024 03-31-2024 10-Q
7 03-15-2024 12-31-2023 10-K
8 11-02-2023 09-30-2023 10-Q
9 08-07-2023 06-30-2023 10-Q
10 05-04-2023 03-31-2023 10-Q
11 03-08-2023 12-31-2022 10-K
12 11-09-2022 09-30-2022 10-Q
13 08-04-2022 06-30-2022 10-Q
14 05-05-2022 03-31-2022 10-Q
15 03-09-2022 12-31-2021 10-K
16 11-15-2021 09-30-2021 10-Q
17 08-05-2021 06-30-2021 10-Q
18 05-06-2021 03-31-2021 10-Q
19 03-09-2021 12-31-2020 10-K
20 11-12-2020 09-30-2020 10-Q
21 08-06-2020 06-30-2020 10-Q
22 05-07-2020 03-31-2020 10-Q
23 03-12-2020 12-31-2019 10-K
24 11-06-2019 09-30-2019 10-Q
25 08-28-2019 06-30-2019 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 morgan-stanley-maintains-overweight-on-mirum-pharmaceuticals-raises-price-target-to-81

Morgan Stanley analyst Michael Ulz maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Overweight and raises the price targ...

 td-cowen-initiates-coverage-on-mirum-pharmaceuticals-with-buy-rating-announces-price-target-of-95

TD Cowen analyst Joseph Thome initiates coverage on Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy rating and announces Pric...

 jp-morgan-maintains-overweight-on-mirum-pharmaceuticals-raises-price-target-to-77

JP Morgan analyst Jessica Fye maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Overweight and raises the price target fr...

 stifel-reinstates-buy-on-mirum-pharmaceuticals-announces-89-price-target

Stifel analyst Dae Gon Ha reinstates Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and announces $89 price target.

 evercore-isi-group-maintains-outperform-on-mirum-pharmaceuticals-raises-price-target-to-89

Evercore ISI Group analyst Gavin Clark-Gartner maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Outperform and raises th...

 jmp-securities-maintains-market-outperform-on-mirum-pharmaceuticals-raises-price-target-to-81

JMP Securities analyst Jonathan Wolleben maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Market Outperform and raises t...

 raymond-james-maintains-strong-buy-on-mirum-pharmaceuticals-raises-price-target-to-82

Raymond James analyst Steven Seedhouse maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Strong Buy and raises the price ...

 hc-wainwright--co-maintains-buy-on-mirum-pharmaceuticals-raises-price-target-to-80

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and raises t...

 mirum-pharmaceuticals-raises-fy2025-sales-guidance-from-435000m-450000m-to-490000m-510000m-vs-448625m-est

Mirum Pharmaceuticals (NASDAQ:MIRM) raises FY2025 sales outlook from $435.000 million-$450.000 million to $490.000 million-$510...

 mirum-pharmaceuticals-q2-eps-012-beats-034-estimate-sales-127785m-beat-107908m-estimate

Mirum Pharmaceuticals (NASDAQ:MIRM) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of...

 hc-wainwright--co-assumes-mirum-pharmaceuticals-at-buy-announces-price-target-of-73

HC Wainwright & Co. analyst Swayampakula Ramakanth assumes Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy rating and ann...

 raymond-james-maintains-strong-buy-on-mirum-pharmaceuticals-raises-price-target-to-77

Raymond James analyst Steven Seedhouse maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Strong Buy and raises the price ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION